Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
Jan 22, 2020
Theramex Acquires Commercial Rights for Oral Contraceptive Zoely
Dec 02, 2019
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Nov 08, 2019
BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA®
Nov 06, 2019
4D pharma plc: Preliminary Safety and Clinical Observations From Its Phase I/II Study of MRx0518 in Combination With KEYTRUDA®
Nov 06, 2019
BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda®
Aug 12, 2019
Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA® (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer
Aug 06, 2019
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
Jun 05, 2019
Global Immunotherapy Drugs Market to 2025: Market will Grow at a CAGR of 12.5% - Key Vendors are AbbVie, Amgen, F. Hoffmann-La Roche, Bristol-Myers Squibb, Johnson & Johnson, & Merck & Co
May 21, 2019
Merck Animal Health Introduces BRAVECTO® Cares to Show Support for the Health of Service Dogs
Apr 30, 2019
The World Market for Esophageal Cancer - Forecast to 2023 with Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche, Merck & Co, and Sanofi Dominating
Apr 26, 2019
Global HDAC (histone deacetylase) Inhibitors Market to 2023 Featuring Celgene, Merck & Co, Novartis, Shenzhen Chipscreen Biosciences, & Spectrum Pharmaceuticals
Apr 15, 2019
Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer
Apr 02, 2019
BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy
Jan 03, 2019
Adlai Nortye Announces Clinical Collaboration with Merck to Evaluate Adlai Nortye's AN0025 (EP4 Antagonist) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Dec 11, 2018
Roche to develop companion diagnostic test to help identify patients eligible for anti-PD-1 therapy based on biomarker expression, not location, of solid tumors
Dec 11, 2018
BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
Nov 07, 2018
OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial
Jul 30, 2018
BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
Jun 26, 2018
Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA®